SEARCH

SEARCH BY CITATION

References

  • 1
    zur Hausen H. Human papilloma viruses and their possible role in squamous cell carcinomas. Curr Top Microbiol Immunol. 1977; 78: 130.
  • 2
    Chan K, Monk BJ, Brewer C, et al. HPV infection and number of lifetime sexual partners are strong predictors for natural regression of CIN 2 and 3. Br J Cancer. 2003; 89: 10626.
  • 3
    Kjellberg L, Wang Z, Wiklund F, et al. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol. 1999; 80: 3918.
  • 4
    Slattery ML, Robison LM, Schuman KL, et al. Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer. JAMA. 1989; 261: 15938.
  • 5
    Brinton LA, Reeves WC, Brenes MM, et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol. 1990; 19: 411.
  • 6
    Alberg AJ, Selhub J, Shah KV, et al. The risk of cervical cancer in relation to serum concentrations of volate, vitamin B12, and homocysteine. Cancer Epidemiol Biomarkers Prev. 2000; 9: 7614.
  • 7
    Fowler BM, Giuliano AR, Piyathilake C, et al. Hypomethylation in cervical tissue: is there a correlation with folate status? Cancer Epidemiol Biomarkers Prev. 1998; 7: 9016.
  • 8
    Bailey LB, Gregory JF 3rd. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr. 1999; 29: 91922.
  • 9
    Friso S, Choi SW, Girelli D, et al. A common mutation in the 5,10 - methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA. 2002; 99: 560611.
  • 10
    Li XL, Xu JH. MTHFR polymorphism and the risk of prostate cancer: a meta-analysis of case–control studies, prostate cancer and prostatic diseases. Neuromolecular Med. 2012; 14: 8490.
  • 11
    Chiusolo P, Reddiconto G, Farina G, et al. MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res. 2007; 31: 166974.
  • 12
    Martin DN, Boersma BJ, Howe TM, et al. Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer. 2006; 6: 25767.
  • 13
    Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther. 2010; 12: R71.
  • 14
    Frosst P, Blom HG, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10: 113.
  • 15
    Mu LN, Cao W, Zhang ZF, et al. Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary hepatocellular carcinoma (HCC) in a Chinese population. Cancer Causes Control. 2007; 18: 66575.
  • 16
    Lewis SJ, Ebrahim S, Smith GD. Meta-analysis of MTHFR 677C[RIGHTWARDS ARROW] T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005; 331: 1053.
  • 17
    Gershoni-Baruch R, Dagan E, Israeli D, et al. Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer. 2000; 36: 23136.
  • 18
    Wiemels JL, Smith RN, Taylor GM, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA. 2001; 98: 40049.
  • 19
    Schnakenberg E, Mehles A, Cario G, et al. Polymorphisms of methylenetetra-hydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet. 2005; 6: 237.
  • 20
    Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004; 4: 14353.
  • 21
    Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science. 1999; 286: 4816.
  • 22
    Costa VL, Henrique R, Ribeiro FR, et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer. 2007; 7: 133.
  • 23
    Khazamipour N, Noruzinia M, Fatehmanesh P, et al. MTHFR promoter hypermethylation in testicular biopsies of patients with non-obstructive azoospermia: the role of epigenetics in male infertility. Hum Reprod. 2009; 24: 23614.
  • 24
    Sun Z, Asmann YW, Kalari KR, et al. Integrated analysis of gene expression, CpG Island methylation, and gene copy number in breast cancercells by deep sequencing. PLoS ONE. 2011; 6: e17490.
  • 25
    Liu R, Yin L, Pu Y. Association between gene expression of metabolizing enzymes and esophageal squamous cell carcinomas in China. Genet Test Mol Biomarkers. 2012; 16: 12117.
  • 26
    Fackler MJ, McVeigh M, Mehrotra J, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 2004; 64: 444252.
  • 27
    Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890907.
  • 28
    Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 1996; 56: 48624.
  • 29
    Kimura F, Franke KH, Steinhoff C, et al. Methyl group metabolism gene polymorphisms and susceptibility to prostatic carcinoma. Prostate. 2000; 45: 22531.
  • 30
    Shen H, Xu Y, Zheng Y, et al. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of gastric cancer in a Chinese population: a case-control study. Int J Cancer. 2001; 95: 3326.
  • 31
    Xu XJ, Zou LW, Wang DB. Cervical cancer with polymorphism in MTHFR C677T gene: a systematic review and meta-analysis. Mol Biol Rep. 2013; 40: 25562.
  • 32
    Luo YL, Ye P, Zhang QH, et al. Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to cervical cancer and cervical intraepithelial neoplasia: a meta-analysis. PLoS ONE. 2012; 7: e46272.
  • 33
    Mei Q, Zhou D, Gao J, et al. The association between MTHFR 677C>Tpolymorphism and cervical cancer: evidence from a meta-analysis. BMC Cancer. 2012; 12: 467.
  • 34
    Osian G, Procopciuc L, Vlad L. MTHFR polymorphisms as prognostic factors in sporadic colorectal cancer. Gastrointestin Liver Dis. 2007; 16: 2516.
  • 35
    Goodman MT, McDuffie K, Hernandez B, et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev. 2001; 10: 127580.
  • 36
    Lambropoulos AF, Agorastos T, Foka ZJ, et al. Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Lett. 2003; 191: 18791.
  • 37
    Agodi A, Barchitta M, Cipresso R, et al. Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in Sicily. Int J Gynecol Cancer. 2010; 20: 1416.
  • 38
    Kang S, Kim JW, Kang GH, et al. Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol. 2005; 96: 17380.
  • 39
    Lai HC, Lin YW, Huang TH, et al. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008; 123: 1617.
  • 40
    Calvisi DF, Simile MM, Ladu S, et al. Altered methionine metabolism and global DNA methylation in liver cancer: relationship with genomic instability and prognosis. Int J Cancer. 2007; 121: 241020.